RxDoctor Payments Data

Ryan McVaigh, PA

Physician Assistant · Schenectady, NYNPI 1083100408

Payments from drug & device makers

$3,595in general payments, 2019–2025

Across 152 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$496
  • Boston Scientific$440
  • AstraZeneca$439
  • Novartis$380
  • Amgen$307
  • Boehringer Ingelheim$262
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,39694%
  • Education$1996%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,595 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$49,827
Medicare patients
697
Services billed
1,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$193,972
EntrestoSacubitril/Valsartan27$44,114
XareltoRivaroxaban26$39,043
JardianceEmpagliflozin19$27,359
Repatha SureclickEvolocumab32$26,821
BrilintaTicagrelor18$19,262
FarxigaDapagliflozin Propanediol12$14,580
OzempicSemaglutide14$13,249
Dofetilide17$3,606
Metoprolol Succinate185$2,431
Rosuvastatin Calcium59$1,978
Atorvastatin Calcium146$1,951
Valsartan30$1,200
Losartan Potassium52$937
Torsemide47$756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$120$193,972158 claims
NovartisEntresto$380$44,11427 claims
Johnson & JohnsonXarelto$43$39,04326 claims
AstraZenecaBrilinta, Farxiga$439$33,84230 claims
Boehringer IngelheimJardiance$262$27,35919 claims
Novo NordiskOzempic$51$13,24914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →